XOMA Royalty (XOMA) Total Liabilities (2010 - 2026)
XOMA Royalty (XOMA) reported Total Liabilities of $159.0 million for Q1 2026, up 24.07% on a YoY basis from $128.1 million in Q1 2025, and down 5.79% sequentially from $168.7 million in Q4 2025.
XOMA Royalty (XOMA) Total Liabilities (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Total Liabilities data on file, last reported at $159.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 24.07% year-over-year to $159.0 million; the trailing twelve-month figure through Mar 2026 stood at $159.0 million (up 24.07% YoY), and the FY2025 full-year result was $168.7 million, up 21.08% from the prior year.
- Total Liabilities retreated to $159.0 million in Q1 2026, from $168.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $168.7 million in Q4 2025 to a low of $15.5 million in Q2 2023.
- A 5-year average of $88.4 million and a median of $129.6 million in 2025 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities slumped 49.61% in 2022 and jumped 822.23% in 2024, its largest moves.
- Tracing XOMA's Total Liabilities over 5 years: stood at $16.4 million in 2022, then surged by 789.42% to $145.6 million in 2023, then dropped by 4.28% to $139.4 million in 2024, then advanced by 21.08% to $168.7 million in 2025, then retreated by 5.79% to $159.0 million in 2026.
- Business Quant data shows XOMA's Total Liabilities at $159.0 million in Q1 2026, $168.7 million in Q4 2025, and $131.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 177.22 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 7.33 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 753.82 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 158.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 158.96 Mn |
| Dec 31, 2025 | 168.74 Mn |
| Jun 30, 2025 | 131.00 Mn |
| Mar 31, 2025 | 128.12 Mn |
| Dec 31, 2024 | 139.36 Mn |
| Sep 30, 2024 | 138.53 Mn |
| Jun 30, 2024 | 143.29 Mn |
| Mar 31, 2024 | 137.08 Mn |
| Dec 31, 2023 | 145.58 Mn |
| Sep 30, 2023 | 18.13 Mn |
| Jun 30, 2023 | 15.54 Mn |
| Mar 31, 2023 | 19.14 Mn |
| Dec 31, 2022 | 16.37 Mn |
| Sep 30, 2022 | 15.81 Mn |
| Jun 30, 2022 | 19.27 Mn |
| Mar 31, 2022 | 19.24 Mn |
| Dec 31, 2021 | 24.69 Mn |
| Sep 30, 2021 | 18.92 Mn |
| Jun 30, 2021 | 19.17 Mn |
| Mar 31, 2021 | 38.17 Mn |